SETAP: epidemiology and prevention of stroke and transient
ischaemic attack in Czech patients with atrial fibrillation

J 2021

SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation

TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA et. al.

Základní údaje

Originální název

SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation

Autoři

TABORSKY, Milos (203 Česká republika), Ladislav DUŠEK (203 Česká republika), Josef KAUTZNER (203 Česká republika), Marek VICHA (203 Česká republika), Renata AIGLOVA (203 Česká republika), Vit GLOGER (203 Česká republika), Marian FEDORCO (203 Česká republika), Jaroslav DUBA (203 Česká republika), Lukas DUSEK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Monika BEZDEKOVA (203 Česká republika) a Tomas SKALA (203 Česká republika, garant)

Vydání

EP Europace, Oxford, Oxford University Press, 2021, 1099-5129

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.486

Kód RIV

RIV/00216224:14110/21:00121729

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1093/europace/euaa261

UT WoS

000644500900009

Klíčová slova anglicky

Atrial fibrillation; Stroke; Epidemiology; Prevalence; Prevention; Anticoagulation; European Union; Czech Republic

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 6. 2021 11:04, Mgr. Tereza Miškechová

Anotace

V originále

Aims The aim of this study is to analyse the prevalence, epidemiology, and anticoagulation prevention of stroke or transient ischaemic attack (TIA) in Czech patients with atrial fibrillation (AF). Methods and results Retrospective observational analysis of diagnoses, procedures, and treatment reported to the Czech National Registry of Reimbursed Healthcare Services between 2015 and 2018. Prevalence of AF in 2018 was 4.3% of Czech population and the prevalence of stroke/TIA in AF patients was 22.3% with annual incidence of 181.62 cases per 100 000 inhabitants. In 2018, CHA(2)DS(2)-ASc score >= 4 was present in 98% AF patients in secondary and 59% in primary prevention, respectively, while the anticoagulation treatment was used by 71-81% of them. Between 2015 and 2018, the percentage of AF patients treated with warfarin monotherapy in primary prevention decreased from 35% to 31%, with acetylsalicylic acid (ASA) monotherapy from 18% to 16% and non-vitamin K antagonist oral anticoagulants (NOACs) monotherapy increased from 7% to 11%. In secondary prevention, the percentage of warfarin monotherapy treatment decreased from 35% to 32%, with ASA monotherapy from 20% to 18% and with NOACs monotherapy increased from 9% to 15%. Conclusion This study followed all Czech patients with AF. The unadjusted prevalence and incidence of AF was higher compared with other countries and 2019 European Society of Cardiology Statistics. The study identified several gaps in standard of reimbursed care. 20-30% of AF patients with other risk factors were without any prevention medication and the share of ASA monotherapy in treated patients was 16-18%.

Citovat

TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA, Vit GLOGER, Marian FEDORCO, Jaroslav DUBA, Lukas DUSEK, Jiří JARKOVSKÝ, Monika BEZDEKOVA a Tomas SKALA. SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation. EP Europace. Oxford: Oxford University Press, 2021, roč. 23, č. 4, s. 539-547. ISSN 1099-5129. Dostupné z: https://dx.doi.org/10.1093/europace/euaa261.

@article{1774647,
   author = {Taborsky, Milos and Dušek, Ladislav and Kautzner, Josef and Vicha, Marek and Aiglova, Renata and Gloger, Vit and Fedorco, Marian and Duba, Jaroslav and Dusek, Lukas and Jarkovský, Jiří and Bezdekova, Monika and Skala, Tomas},
   article_location = {Oxford},
   article_number = {4},
   doi = {http://dx.doi.org/10.1093/europace/euaa261},
   keywords = {Atrial fibrillation; Stroke; Epidemiology; Prevalence; Prevention; Anticoagulation; European Union; Czech Republic},
   language = {eng},
   issn = {1099-5129},
   journal = {EP Europace},
   title = {SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation},
   url = {https://academic.oup.com/europace/article-abstract/23/4/539/6030920?redirectedFrom=fulltext},
   volume = {23},
   year = {2021}
}

TY  - JOUR
ID  - 1774647
AU  - Taborsky, Milos - Dušek, Ladislav - Kautzner, Josef - Vicha, Marek - Aiglova, Renata - Gloger, Vit - Fedorco, Marian - Duba, Jaroslav - Dusek, Lukas - Jarkovský, Jiří - Bezdekova, Monika - Skala, Tomas
PY  - 2021
TI  - SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation
JF  - EP Europace
VL  - 23
IS  - 4
SP  - 539-547
EP  - 539-547
PB  - Oxford University Press
SN  - 10995129
KW  - Atrial fibrillation
KW  - Stroke
KW  - Epidemiology
KW  - Prevalence
KW  - Prevention
KW  - Anticoagulation
KW  - European Union
KW  - Czech Republic
UR  - https://academic.oup.com/europace/article-abstract/23/4/539/6030920?redirectedFrom=fulltext
N2  - Aims The aim of this study is to analyse the prevalence, epidemiology, and anticoagulation prevention of stroke or transient ischaemic attack (TIA) in Czech patients with atrial fibrillation (AF). Methods and results Retrospective observational analysis of diagnoses, procedures, and treatment reported to the Czech National Registry of Reimbursed Healthcare Services between 2015 and 2018. Prevalence of AF in 2018 was 4.3% of Czech population and the prevalence of stroke/TIA in AF patients was 22.3% with annual incidence of 181.62 cases per 100 000 inhabitants. In 2018, CHA(2)DS(2)-ASc score >= 4 was present in 98% AF patients in secondary and 59% in primary prevention, respectively, while the anticoagulation treatment was used by 71-81% of them. Between 2015 and 2018, the percentage of AF patients treated with warfarin monotherapy in primary prevention decreased from 35% to 31%, with acetylsalicylic acid (ASA) monotherapy from 18% to 16% and non-vitamin K antagonist oral anticoagulants (NOACs) monotherapy increased from 7% to 11%. In secondary prevention, the percentage of warfarin monotherapy treatment decreased from 35% to 32%, with ASA monotherapy from 20% to 18% and with NOACs monotherapy increased from 9% to 15%. Conclusion This study followed all Czech patients with AF. The unadjusted prevalence and incidence of AF was higher compared with other countries and 2019 European Society of Cardiology Statistics. The study identified several gaps in standard of reimbursed care. 20-30% of AF patients with other risk factors were without any prevention medication and the share of ASA monotherapy in treated patients was 16-18%.
ER  -

TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA, Vit GLOGER, Marian FEDORCO, Jaroslav DUBA, Lukas DUSEK, Jiří JARKOVSKÝ, Monika BEZDEKOVA a Tomas SKALA. SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation. \textit{EP Europace}. Oxford: Oxford University Press, 2021, roč.~23, č.~4, s.~539-547. ISSN~1099-5129. Dostupné z: https://dx.doi.org/10.1093/europace/euaa261.

Podrobný výpis o publikaci